文献速递前列腺增生与排尿功能障碍

高频不可逆电穿孔治疗良性前列腺增生:随机对照开放标签多中心临床研究

Efficacy and Safety of High-Frequency Irreversible Electroporation in Benign Prostatic Hyperplasia: A Randomized Controlled, Open-label, Multi-Center Clinical Study.
PubMed 文献 · Urology · 2025-03-21

一项随机对照开放标签多中心研究将160例良性前列腺增生受试者随机分为高频不可逆电穿孔消融组和坦索罗辛0.2 mg/日对照组,评估治疗前及治疗后1、3、12个月的最大尿流率、前列腺体积、IPSS和IIEF-5评分。结果显示试验组在12个月随访期内Qmax、前列腺体积和IPSS改善,安全性良好,且对大、中、小前列腺体积患者均显示显著疗效和安全性。

要点

  • 试验组与对照组在1、3、12个月Qmax改善分别为1.22±5.50 vs 1.75±4.29、8.41±8.23 vs 2.61±5.53、7.67±7.63 vs 4.31±6.76 mL/s。
  • 试验组3个月和12个月IPSS改善显著高于对照组,1个月时除外。
  • 试验组3个月前列腺体积缩小亦被观察到,两组不良事件发生率均低。

核心结论

  • 试验组在12个月随访期内Qmax、前列腺体积和IPSS均改善,安全性良好。
  • 高频不可逆电穿孔消融对大、中、小前列腺体积患者均显示显著疗效和安全性。

研究设计与样本

  • 随机对照开放标签多中心临床研究,160例受试者随机分为试验组(接受消融)和对照组(接受坦索罗辛0.2 mg/日)。
  • 评估治疗前及治疗后1、3、12个月的最大尿流率、前列腺体积、国际前列腺症状评分和国际勃起功能指数5项评分,并记录不良事件。
  • 另按基线前列腺体积三分位法将患者分为三组进行亚组分析。

主要发现

  • 试验组与对照组在1、3、12个月Qmax改善分别为1.22±5.50 vs 1.75±4.29、8.41±8.23 vs 2.61±5.53、7.67±7.63 vs 4.31±6.76 mL/s。
  • 试验组3个月和12个月IPSS改善显著高于对照组,1个月时除外。
  • 试验组3个月前列腺体积缩小亦被观察到。
  • 两组不良事件发生率均低。
  • 亚组分析显示各亚组间关键指标无统计学差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of high-frequency irreversible electroporation for ablation of benign prostatic hyperplasia. MATERIALS AND METHODS: One hundred sixty subjects were randomly assigned to the test group to receive ablation and the control group to receive 0.2 mg/day tamsulosin. The maximum urinary flow rate (Qmax), prostate volume, and International Prostate Symptom Score (IPSS), and International Index of Erectile Function 5-item score were evaluated before treatment and 1, 3, and 12 months after treatment. Differences inter-group and changes intra-group over different follow-up periods were evaluated, and adverse events were recorded. At the same time, patients were divided into three groups according to the tertile method of the baseline prostate volume, and the above indicators were also analyzed. RESULTS: Qmax improvement in the test group and control group at 1, 3 and 12 months were 1.22 ± 5.50 and 1.75 ± 4.29, 8.41 ± 8.23 and 2.61 ± 5.53, 7.67 ± 7.63, and 4.31 ± 6.76 mL/s, respectively. IPSS improvement in the test group at 3 and 12 months were significantly higher than that in the control group, except for 1 month. Similarly, the reduction in prostate volume at 3 months was also observed. The incidences of adverse events were low in both groups. Subgroup analysis showed that there were no statistical differences in key indicators among subgroups. CONCLUSION: Qmax, prostate volume, and IPSS were improved in the test group during the 12-month follow-up, and the safety profile was favorable. High-frequency irreversible electroporation ablation demonstrated significant efficacy and safety for all patients with large, medium, and small prostate volumes.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Tong Z, Yang Z, Dong B, et al. Efficacy and Safety of High-Frequency Irreversible Electroporation in Benign Prostatic Hyperplasia: A Randomized Controlled, Open-label, Multi-Center Clinical Study. Urology. 2025. PMID: 40122290. doi:10.1016/j.urology.2025.03.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。